Skip to search formSkip to main contentSkip to account menu

nimotuzumab

Known as: Immunoglobulin G1, anti-(humanized mouse monoclonal hR3 beta1 chain anti-human epidermal growth factor receptor), disulfide with humanized mouse monoclonal hR3 kappa-chain, dimer 
A monoclonal antibody being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (1)

Antibodies, Monoclonal, Humanized
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibitionantigen binding

Narrower (2)

TheraCIMTheraloc

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma
We assessed the efficacy and safety of nimotuzumab plus neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for… 
2013
2013
Treatment of children with high grade glioma with nimotuzumab: A 5-y institutional experience
Brain tumors are a major cause of cancer-related mortality in children. Overexpression of epidermal growth factor receptor (EGFR… 
Review
2012
Review
2012
Final results of a randomized phase III trial of nimotuzumab for the treatment of newly diagnosed glioblastoma in addition to standard radiation and chemotherapy with temozolomide versus standard…
2033 Background: The receptor for epidermal growth factor (EGF-R) has consistently been found expressed or overexpressed in human… 
Highly Cited
2011
Highly Cited
2011
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor
Engineered domains of human fibronectin (Adnectins™) were used to generate a bispecific Adnectin targeting epidermal growth… 
2010
2010
An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb…
5530 Background: h-R3mAb (nimotuzumab) is a humanized monoclonal antibody targeting epidermal growth factor receptor (EGFR). EGFR… 
2008
2008
Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas
ObjectiveTo evaluate the biodistribution, internal radiation dosimetry and safety of the 188Re-labelled humanized monoclonal… 
2008
2008
Phase III trial of nimotuzumab for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents
2058 Background: Despite multimodal therapy children with newly diagnosed intrinsic pontine glioma (PG) have a dismal prognosis… 
2007
2007
Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents
Background Despite multimodal therapy most children with high grade gliomas (HGG), including glioblastoma multiforme (GM… 
Review
2005
Review
2005
Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience.
  • J. Spicer
  • Current opinion in molecular therapeutics (Print)
  • 2005
  • Corpus ID: 27175085
A joint venture between YM BioSciences (formerly York Medical) and The Center of Molecular Immunology is collaborating with… 
2002
2002
A phase I study of 99mTc-hR3 (DiaCIM®), a humanized immunoconjugate directed towards the epidermal growth factor receptor
A phase I trial was conducted to evaluate the safety, tumour and normal tissue localization, pharmacokinetics and radiation… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)